vs
Side-by-side financial comparison of Seritage Growth Properties (SRG) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $4.2M, roughly 1.3× Seritage Growth Properties). On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -4.9%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -15.0%).
Seritage Growth Properties is a U.S.-headquartered publicly traded real estate investment trust. It owns, redevelops, and manages a diversified portfolio of retail, residential, and mixed-use commercial properties across key U.S. markets, leasing spaces to retail, dining, and service sector tenants.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
SRG vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.2M | $5.5M |
| Net Profit | — | $-27.9M |
| Gross Margin | — | — |
| Operating Margin | — | -516.0% |
| Net Margin | — | -507.8% |
| Revenue YoY | -4.9% | 171.3% |
| Net Profit YoY | 55.2% | -48.3% |
| EPS (diluted) | — | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.2M | $5.5M | ||
| Q3 25 | $4.8M | $0 | ||
| Q2 25 | $4.7M | $2.0M | ||
| Q1 25 | $4.6M | $2.3M | ||
| Q4 24 | $4.4M | $2.0M | ||
| Q3 24 | $3.3M | $1.8M | ||
| Q2 24 | $4.2M | $1.1M | ||
| Q1 24 | $5.8M | $3.4M |
| Q4 25 | — | $-27.9M | ||
| Q3 25 | $-12.4M | $-32.7M | ||
| Q2 25 | $-28.5M | $-26.9M | ||
| Q1 25 | $-22.2M | $-21.5M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | $-22.0M | $-25.5M | ||
| Q2 24 | $-101.2M | $-20.9M | ||
| Q1 24 | $-19.0M | $-24.1M |
| Q4 25 | — | -516.0% | ||
| Q3 25 | -258.0% | — | ||
| Q2 25 | -610.2% | -1347.1% | ||
| Q1 25 | -486.9% | -930.5% | ||
| Q4 24 | — | -985.8% | ||
| Q3 24 | -673.2% | -1448.4% | ||
| Q2 24 | -2366.1% | -1915.4% | ||
| Q1 24 | -328.7% | -713.3% |
| Q4 25 | — | -507.8% | ||
| Q3 25 | -259.6% | — | ||
| Q2 25 | -612.6% | -1353.6% | ||
| Q1 25 | -482.8% | -935.2% | ||
| Q4 24 | — | -929.0% | ||
| Q3 24 | -675.9% | -1427.5% | ||
| Q2 24 | -2401.0% | -1882.0% | ||
| Q1 24 | -328.9% | -705.4% |
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-0.24 | $-0.09 | ||
| Q2 25 | $-0.53 | $-0.09 | ||
| Q1 25 | $-0.42 | $-0.08 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | $-0.41 | $-0.10 | ||
| Q2 24 | $-1.82 | $-0.09 | ||
| Q1 24 | $-0.36 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $48.1M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $331.4M | $246.9M |
| Total Assets | $393.8M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $48.1M | $319.8M | ||
| Q3 25 | $51.5M | $297.3M | ||
| Q2 25 | $71.8M | $312.8M | ||
| Q1 25 | $94.3M | $116.6M | ||
| Q4 24 | $85.2M | $139.0M | ||
| Q3 24 | $85.6M | $157.7M | ||
| Q2 24 | $86.7M | $172.7M | ||
| Q1 24 | $114.9M | $124.0M |
| Q4 25 | $331.4M | $246.9M | ||
| Q3 25 | $337.7M | $219.0M | ||
| Q2 25 | $351.4M | $248.7M | ||
| Q1 25 | $381.1M | $55.1M | ||
| Q4 24 | $404.5M | $71.5M | ||
| Q3 24 | $417.5M | $88.8M | ||
| Q2 24 | $440.4M | $108.9M | ||
| Q1 24 | $542.4M | $53.8M |
| Q4 25 | $393.8M | $343.3M | ||
| Q3 25 | $558.6M | $316.6M | ||
| Q2 25 | $575.7M | $333.3M | ||
| Q1 25 | $649.7M | $138.4M | ||
| Q4 24 | $677.8M | $160.4M | ||
| Q3 24 | $735.0M | $180.2M | ||
| Q2 24 | $758.3M | $200.4M | ||
| Q1 24 | $914.6M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.9M | $-26.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.9M | $-26.7M | ||
| Q3 25 | $-12.5M | $-24.2M | ||
| Q2 25 | $-12.0M | $-20.2M | ||
| Q1 25 | $-9.2M | $-22.0M | ||
| Q4 24 | $-53.5M | $-18.3M | ||
| Q3 24 | $-15.5M | $-21.6M | ||
| Q2 24 | $-7.5M | $-21.5M | ||
| Q1 24 | $-16.6M | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-24.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | — | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 18.1% | ||
| Q1 24 | — | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
